The Down Under medical sector is excited with the emergence of retatrutide, a novel dual GIP and GLP-1 receptor showing impressive results in clinical trials for treating obesity. This therapy suggests a https://tvsocialnews.com/story7408085/retatrutide-australia-australia-a-new-hope-for-weight-loss